L. Casali (Terni, Italy), P. Kelly (Dublin, Ireland)
Determination of drug susceptibility of Mycobacterium tuberculosis through mycolic acid analysis with HPLC technique - comparison to the conventional methods R. Walkiewicz, H. Grubek-Jaworska, R. Chazan (Warsaw, Poland)
| |
3D-CT evaluation of endobronchial tuberculosis during aerosol therapy with corticosteroid and streptomycin Y. Kido, T. Rikimaru, Y. Sueyasu, T. Koga, H. Aizawa (Kurume, Japan)
| |
High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB A. B. Younossian, J. P. Ketterer, J. Wacker, T. Rochat, J. P. Janssens (Geneva, La Chaux-de-Fonds, Switzerland)
| |
Nontuberculous mycobacteriosis - from diagnosis to therapy V. Bartu, I. Hricikova, E. Kopecka, M. Vasakova (Prague, Czech Republic)
| |
Bone and joint tuberculosis in Bradford: a 6 year review (1999-2004) D. Saralaya, A. Dwarakanath, R. Frizzell, D. Newton, B. Jacob, P. McWhinney (Bradford, United Kingdom)
| |
Frequency of venous thromboembolism among patients with tuberculosis M. Ambrosetti, A. Sarassi, P. Viggiani, G. Besozzi, L. Codecasa, M. Ferrarese, R. Centis, G. B. Migliori (Tradate, Sondalo, Milan, Italy)
| |
Assessment of sputum Mycobacterium tuberculosis messenger RNA levels in anti-microbial treatment monitoring S. Chocholska, H. Potoczna, M. Dabrowska, R. Kieszko, A. Krol, P. Krawczyk, J. Milanowski (Lublin, Poland)
| |
Peripheral blood leukocyte subsets as markers of early TB treatment response H. Veenstra, R. Baumann, M. Kidd, N. Caroll, P. T. Luckey, N. Beyers, C. T. Bolliger, P. D. van Helden, G. Walzl (Tygerberg, South Africa; Stevenage, United Kingdom)
| |